Abbisko's pimicotinib wins FDA approval; Akeso/Summit awaits ivonescimab decision; Windward Bio files US IPO
Summary
The hosts discuss Abbisko's pimicotinib receiving FDA approval for tenosynovial giant cell tumor, noting the trial's significant Chinese patient inclusion under Project AUBIS. They highlight Merck KGaA's commercial rights and the milestone payment structure. The episode covers the upcoming November 14 FDA decision for Akeso and Summit's ivonescimab, focusing on the statistical significance of overall survival data. Additional topics include South Korea's new policy allowing travelers to import GLP-1 drugs, Windward Bio's US IPO filing, ImvivaBio's lupus CAR-T data, Shionogi's licensing deal in Singapore, and Neuralink's expanded PRIME 2 trial.
Key takeaways
- 1 it includes people with severe arm impairment from a long-standing ischemic stroke, alongside spinal cord injury and ALS.
Unidentified speaker (speaker_0) · 10:03
Episode sections
- 0:04 – 0:50
Intro and AI-voice disclosure
Hosts introduce the show, disclose AI voice cloning, and state the episode's date and theme.
- 0:50 – 3:30
Abbisko's pimicotinib, China then US
Ning reports FDA approval of Abbisko's pimicotinib for tenosynovial giant cell tumor after approvals in China, Canada, and Switzerland. Speaker_0 notes the trial included nearly half Chinese patients and Merck KGaA holds commercial rights.
- 3:30 – 4:54
Akeso and Summit's ivonescimab date
Ning states the FDA decision date for Akeso/Summit's ivonescimab is Saturday, November 14. Speaker_0 discusses the Global Harmony trial results, noting progression-free survival met goals but overall survival was not statistically significant at the main analysis.
- 4:54 – 6:06
Korea lets in GLP-1 drugs bought abroad
Ning reports South Korea's MFDS allows travelers to import prescribed obesity drugs like Wegovy and Mounjaro. Speaker_0 explains the limit is six containers or three months' supply, citing price arbitrage as a driver.
- 6:06 – 7:28
Windward Bio's IPO, Chinese antibodies
Speaker_0 reports Windward Bio's US IPO filing for ~$175M at $16-18/share. Ning details its lead drug is an asthma antibody licensed from Kelun-Biotech and Harbour BioMed, with Sanofi investing $50M in a private placement.
- 7:28 – 8:54
CTA313: off-the-shelf CAR-T for lupus
Ning presents ImvivaBio's CTA313 data from the ACR meeting, showing 7/8 patients in remission at 12 months. Speaker_0 notes the study was small, uncontrolled, and conducted in China, with a global Phase 1B planned.
- 8:54 – 9:51
Shionogi's cefiderocol and Singapore
Ning reports Shionogi licensed cefiderocol to Singapore-based Link Healthcare for Singapore and Malaysia. Speaker_0 notes this extends an existing Australia/New Zealand partnership and highlights the regulatory mode of using a local partner for Southeast Asia.
- 9:51 – 13:35
Neuralink's PRIME 2 adds stroke
Speaker_0 reports Neuralink's PRIME 2 trial now includes stroke patients alongside spinal cord injury and ALS. Ning discusses the US proposal to bar new investment in Chinese BCI companies, noting comments close December 7.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| SanofiSNY | equity | neutral | And Sanofi has agreed to buy $50 million of shares in a private placement alongside the offering. |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
Pimicotinib (Pimjetmi) was approved by the US FDA on November 10, 2026, for tenosynovial giant cell tumor.
Ning ·0:50
How to verify: US FDA approval letter and press release for Abbisko; FDA database search for NDA 200xxx. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
China's regulator approved pimicotinib first in December 2025.
Unidentified speaker (speaker_0) ·1:21
How to verify: NMPA (China) drug approval database for Abbisko/pimicotinib. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Health Canada approved pimicotinib in June 2026.
Unidentified speaker (speaker_0) ·1:21
How to verify: Health Canada Drug Product Database for pimicotinib. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Switzerland's Swiss Medic approved pimicotinib in October 2026.
Unidentified speaker (speaker_0) ·1:21
How to verify: Swissmedic approval database for pimicotinib. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Merck KGaA holds worldwide commercial rights for pimicotinib and receives a $20 million milestone payment on first US sale plus double-digit royalties.
Unidentified speaker (speaker_0) ·1:40
How to verify: Abbisko or Merck KGaA press release detailing the licensing agreement terms; Summit Q3 2026 filing if Abbisko is a subsidiary or partner. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceIn the Phase 3 maneuver trial, 45 of 94 patients were in China, and 56% on pimicotinib had tumor response vs 3% on placebo at week 25.
Ning ·2:10
How to verify: FDA clinical review summary for pimicotinib; Abbisko clinical trial results publication. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
The FDA decision date for ivonescimab is Saturday, November 14, 2026.
Ning ·3:30
How to verify: FDA OASIS database for Akeso/Summit ivonescimab PDUFA date. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
The Global Harmony trial met its progression-free survival goal, but overall survival was not statistically significant at the main analysis.
Unidentified speaker (speaker_0) ·3:56
How to verify: Summit Therapeutics press release or SEC filing (8-K/10-Q) detailing Global Harmony trial results. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceSummit reported a survival hazard ratio of 0.76 for ivonescimab, which is nominally significant but not the trial's formal preset test.
Ning ·4:12
How to verify: Summit Therapeutics investor presentation or SEC filing discussing the Global Harmony trial interim analysis. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceWindward Bio is seeking about $175 million on Nasdaq at $16 to $18 a share in its November 9 filing.
Unidentified speaker (UNKNOWN) ·6:06
How to verify: Windward Bio S-1 filing on SEC EDGAR dated November 9, 2026. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.
Primary sourceDo your own research
- Verify Abbisko's pimiotinib FDA approval letter and Project AUBIS collaboration details via FDA.gov.
- Check Summit Therapeutics' Q3/Q4 filings for ivonescimab overall survival hazard ratio and statistical analysis plan.
- Review South Korea MFDS customs guidelines for GLP-1 import limits and local pharmacy pricing data.
- Examine Windward Bio's S-1 filing for IPO size, share price range, and Sanofi investment terms.
- Assess ImvivaBio's CTA313 Phase 1B trial design and primary endpoints for lupus remission validation.
- Confirm Shionogi's licensing agreement terms with Link Healthcare for Southeast Asia rights.
- Monitor Neuralink's PRIME 2 trial registry updates for stroke patient inclusion criteria.
- Check US Treasury/Commerce Department notices on Chinese BCI investment restrictions and comment period deadlines.
Full transcriptexpand
- 0:04
- Unidentified speaker (UNKNOWN): A
- 0:05
- Unidentified speaker (speaker_0): pill discovered in Shanghai won US approval on Tuesday after China, Canada, and Switzerland said yes first. Almost half its key trials patients were in China. Ivanessimaps FDA deadline on Saturday Today is the next test of Eastern data.
- 0:24
- Unidentified speaker (UNKNOWN): I'm
- 0:25
- Unidentified speaker (speaker_0): Basil Louis, Investing Global. globally from Singapore with an Asia angle. This is the East West Bio Brief, Biotech and Beyond, for Thursday, November 12th.
- 0:37
- Unidentified speaker (UNKNOWN): And
- 0:37
- Ning: I'm Ning, Basil's AI co-host. Both our voices are AI clones, but Basil is the real person behind this show. Personal views, not investment advice.
- 0:50
- Ning: Pimikutinip, in Chinese, Pimitini, sold in the US as Pimjetmi, is a once-daily pill from Shanghai-based abysco in Chinese, Hyu Yao. On November 10th, the US FDA approved it for adults with tanosynovial giant cell tumor, a rare tumor that grows in the
- 1:10
- Ning: lining of joints and tendons, causing pain, swelling, and stiffness. It's for patients where surgery could make function worse or cause serious harm.
- 1:21
- Unidentified speaker (speaker_0): The order of approvals is the east-west story. China's regulator approved it first in December 2025. Then Health Canada in June, Switzerland's Swiss Medic in October, and now the FDA. Germany's Merck KGAA holds the worldwide commercial rights.
- 1:40
- Unidentified speaker (speaker_0): Habisco says it gets a $20 million milestone payment on the first US sale plus double digit royalties on global sales.
- 1:50
- Ning: And the evidence? In the phase three maneuver trial, 94 patients were randomized, two to one to the pill or a placebo. 45 Forty-five of them were in China and 49 in the US. Canada, and Europe. At week 25, 56% on permacotinip had a tumor response on scans, against about
- 2:10
- Ning: 3% on placebo.
- 2:11
- Unidentified speaker (speaker_0): The FDA also reports improvements in joint movement, pain, and physical function. The label carries warnings on liver injury and on harm to an unborn baby.
- 2:22
- Ning: So, why should a rare joint tumor matter? to anyone outside that field?
- 2:30
- Unidentified speaker (speaker_0): Because of how the evidence was built.
- 2:33
- Unidentified speaker (UNKNOWN): The
- 2:33
- Unidentified speaker (speaker_0): FDA notes the trial was stratified by China versus the rest of the world from the start and it accepted a package with almost half its patients in China. The review also ran under Project AUBIS, Aubys, where the FDA works alongside regulators including Australia, Canada,
- 2:51
- Unidentified speaker (speaker_0): Switzerland, and the UK.
- 2:53
- Unidentified speaker (UNKNOWN): And
- 2:54
- Ning: there's a Singapore angle. The Health Sciences Authority has a verification route for new drugs already approved by at least two of its six reference regulators, among other conditions. The FDA, the European Medicines Agency, Health Canada, Britain's MHRA, Swiss Medic, and Australia's TGA. China's regulator
- 3:13
- Ning: isn't on that list.
- 3:15
- Unidentified speaker (speaker_0): So for Singapore, it's the Western approvals that count, even though China said yes first. We don't know whether anyone has filed in Singapore, but this is our regulatory mode thread: who gets to sell what where.
- 3:30
- Ning: Which brings us to this weekend. The FDA's EA's target date for Ivor Ivonesimap Nessimap is Saturday, is Saturday, November 14th. It was invented by Arkeso. Ake So in Chinese, Kang Feng Shengwu, and licensed to summit therapeutics for markets including the US, Europe, and Japan.
- 3:46
- Unidentified speaker (speaker_0): The application is for IvonesciMap with chemotherapy in lung cancer with an EGFR mutation after targeted pills have stopped working.
- 3:55
- Unidentified speaker (UNKNOWN): The
- 3:56
- Unidentified speaker (speaker_0): Global Harmony trial met its goal on progression-free progression free survival, how long patients lived before the cancer grew. But at the main analysis, overall survival was not statistically significant, and the FDA had said it needs that.
- 4:12
- Ning: Summit says a June update showed a survival hazard ratio of 0.76 across all patients, and the same figure in Western patients. Summit reports the overall figure as nominally significant, meaning it isn't the trial's formal preparation. preset test. And in the Western group, the range of uncertainty still
- 4:32
- Ning: includes no benefit.
- 4:33
- Unidentified speaker (speaker_0): As of our morning news card, there was no FDA action. We won't guess the outcome. The FDA could approve, reject, or the timeline could move. Either way, it's the live test for our where do the patients come from threat and we'll come back to it on Monday.
- 4:54
- Ning: From today, South Korea lets travelers bring in obesity drugs such as Wagovi and Maojaro if they were properly prescribed and bought abroad. The drug regulator, the MFDS, announced it with the Customs Service on Wednesday.
- 5:12
- Unidentified speaker (speaker_0): The basic limit is six containers.
- 5:15
- Unidentified speaker (speaker_0): or more if it stays within three months supply. For once weekly injection, Yonhep puts that at twelve to thirteen pence. Buying medicines directly from overseas online is still banned, and narcotics and psychotropic drugs are excluded.
- 5:33
- Ning: Why the change?
- 5:35
- Unidentified speaker (speaker_0): Korean media say these drugs had effectively been stopped at customs, even with a valid foreign prescription. Mojaro bought more cheaply in Japan, even earned a nickname in Korea, Sushijaro. Yonhep also reports a concern that more people may now travel abroad for prescriptions.
- 5:52
- Ning: This is our GLP1 thread, and it's a regulatory story, not a science one. The molecule is the same in Seoul and Tokyo. A customs rule decides whether the price gap matters.
- 6:06
- Unidentified speaker (UNKNOWN): In
- 6:07
- Unidentified speaker (speaker_0): US listings, Basel-based Windward Bio is seeking about $175 million on Nasdaq at $16 to $18 a share, according to its November 9th filing. It hadn't priced by our morning news newscard card, and IPO trackers expect trading to start on Friday US time.
- 6:27
- Ning: Its lead drug is a long-acting asthma antibody licensed from two Chinese companies, Kelun Biotech in Chinese, Kilun Botai, and Haber Biomed in Chinese, Hpo Yiyang. Windward holds the global rights outside Greater China and certain
- 6:47
- Ning: Asian countries. Its second drug, an antibody, that hits two targets, is licensed from Kyunz in Chinese, Chuan Sin Shengwu.
- 6:57
- Unidentified speaker (speaker_0): And Sanofi has agreed to buy $50 million of shares in a private placement alongside the offering.
- 7:05
- Ning: So, a Swiss company, Chinese molecules, and American public money.
- 7:10
- Unidentified speaker (speaker_0): That's the new co co-model, model, and it's our China as big farmers. RD lab thread. The Chinese inventors keep their home markets and a Western company carries the global trials and the US listing. The first test is how the deal prices
- 7:28
- Unidentified speaker (UNKNOWN): From
- 7:28
- Ning: the ACR rheumatology meeting, a cell therapy built in China. CTA313 is a donor donor-derived derived off-the-shelf car CART. tea. It targets two markers on antibody-making B cells, CD19 and BCMA, aiming to wipe them out and let the immune system restart. Boston-based
- 7:48
- Ning: Inviva Bio is presenting the data. The phase one studies were run in China, and the earlier work was sponsored by Nanjing-based biohang therapeutics.
- 7:57
- Unidentified speaker (UNKNOWN): In
- 7:57
- Unidentified speaker (speaker_0): a pooled analysis of 14 heart-to-treat hard-to-treat lupus patients, seven 7 of the eight assessment. 8 assessed at 12 months were in Doris remission, a strict definition of remission. Cytokine release syndrome occurred in about a third of patients, all of it grade 1, with no neurotoxicity. But serious drops in white
- 8:17
- Unidentified speaker (speaker_0): blood cells were common in about 7 in 10 patients.
- 8:22
- Ning: So is this ready for patients outside China?
- 8:27
- Unidentified speaker (speaker_0): Not yet. It's small, uncontrolled, and company reported. The next step is a global phase 1B basket study after a US FDA clearance in June. For our China as RD lab threat, this is the pattern. Patients and early data in
- 8:47
- Unidentified speaker (speaker_0): China. Then a US company carries it into global trials.
- 8:53
- Ning: Closer to home, Japan's Shionogi has licensed its antibiotics CephideroCol to Singapore-based Link Healthcare, part of Clinigen, for Singapore and Malaysia. Cephiderokol gets through the outer wall of gram-negative bacteria, including multi-drug Drug resistant strains. streams.
- 9:10
- Unidentified speaker (speaker_0): Link gets exclusive rights in both countries and will handle the regulatory filings, approvals, and launch. Shionogi's release lists the drug as sold in Japan, the US, Europe, Taiwan, and South Korea. Singapore and Malaysia aren't on that list yet.
- 9:29
- Unidentified speaker (UNKNOWN): The
- 9:29
- Unidentified speaker (speaker_0): deal extends an existing Shionogi and Link partnership in Australia and New Zealand. Financial terms weren't disclosed.
- 9:38
- Ning: That's our regulatory mode threat again. A Japanese drug with US and European approvals already in hand reaches Southeast Asia through a Singapore-based partner that will handle the local filings.
- 9:51
- Unidentified speaker (speaker_0): In Brain Computer Interfaces, Neuralink has a new early feasibility study, Prime 2, posted on clinicaltrials.gov on November 10th.
- 10:02
- Unidentified speaker (UNKNOWN): For the
- 10:02
- Unidentified speaker (speaker_0): first time,
- 10:03
- Unidentified speaker (speaker_0): it includes people with severe arm impairment from a long-standing ischemic stroke, alongside spinal cord injury and ALS.
- 10:13
- Unidentified speaker (UNKNOWN): It
- 10:13
- Ning: plans up to 10 adults at up to 5 US centers, with the University of Miami the only site listed so far. Participants would control a computer cursor or a virtual keyboard using using signals from an implant placed by Neuralink's surgical robot. There's no control
- 10:33
- Ning: group. The focus is safety, plus early signs of usefulness.
- 10:38
- Unidentified speaker (UNKNOWN): The
- 10:38
- Unidentified speaker (speaker_0): East West Line runs through our brain race thread. Washington has proposed barring new US investment in Chinese companies that develop or produce brain computer interfaces. with listed shares exempted. Comments close on December 7th and the rule isn't final. So while
- 10:58
- Unidentified speaker (speaker_0): American trials widen, the funding question for China's BCI companies is being rewritten. We'll dig into that in a Monday episode soon.
- 11:10
- Ning: Beyond biotech, a wearable from China. Researchers at Guangxi University, working with Tsinghua University and others, have published a new gel electrode for EEG caps, the kind that read brain signals through the scalp.
- 11:29
- Unidentified speaker (speaker_0): It's soft where it touches the scalp and firm where it meets the electronics. In the paper, it recorded stable signals for more than eight years. 8 hours while the wearer moved around and more than 14 hours at rest. Typing accuracy stayed above 94% in a test where users spell
- 11:49
- Unidentified speaker (speaker_0): by looking at a flickering on-screen keyboard.
- 11:53
- Ning: It was tested on very few people, so this is an engineering result,
- 12:00
- Ning: not a product.
- 12:01
- Unidentified speaker (speaker_0): And from Korea, Ray Watt, which makes imaging devices for blood vessels, raised 13 billion one in a series B. Its faster system uses OCT, a light-based scan of the inside of heart arteries, at up to 400 frames a second.
- 12:19
- Ning: The company says it has approval to sell in Vietnam and a first export to the UAE. And it's now working towards the USFDA. So an Asian device maker is going regional first, then West.
- 12:37
- Ning: So back to our opening question. Pimi Cottenip shows that a trial built from the start to compare China with the rest of the world, with almost half its patients in China can get through the FDA. FTE.
- 12:50
- Unidentified speaker (speaker_0): Ivona Schema is the harder case because the survival number is the question. And in Korea, from today, a customs rule, not a patent, decides where people can buy their obesity drugs. If this brief is useful, follow the East West BioBrief on Spotify
- 13:10
- Unidentified speaker (speaker_0): or Apple Podcasts.
- 13:12
- Unidentified speaker (UNKNOWN): And
- 13:12
- Ning: for the transcripts and sources, subscribe to our new. newsletter on LinkedIn, also called the East West Bio Brief. It goes out every Monday with our weekly roundup. That's today's brief. The key sources are in the show notes. See you tomorrow.
More from The East-West Bio Brief
Daily, Sun 15 Nov: Beijing adds 107 drugs, Europe says yes. Who wins?
Episode discussion: China adds 107 drugs to insurance list; Europe backs lung cancer treatments; FDA decision pending for ivonescimab
Speakers’ claims: Speakers report that China's National Healthcare Security Administration added 107 new drugs to its 2026 National Reimbursement Drug List, including a record 51 Class 1 innovative drugs. JW Therapeutics' CAR-T therapy and Novo Nordisk's insulin-semaglutide combination were highlighted as notable additions. In Europe, the EMA's CHMP backed Hansoh's aumolertinib and Innovent's sintilimab for lung cancer. Meanwhile, the FDA's decision on Akeso's ivonescimab remained pending as of the episode's recording. The speakers also discussed US regulatory restrictions on genetic data exports and their impact on clinical trials.
Daily, Sat 14 Nov: FDA decision day for ivonescimab, Akeso's lung cancer bispecific
Episode discussion: FDA decision day for Akeso's ivonescimab; BioNTech buys voucher; Intellia deadline set
Speakers’ claims: Basil Lui and AI co-host Ning discuss the November 14 FDA decision deadline for Akeso's ivonescimab, a PD1/VEGF bispecific licensed to Summit Therapeutics. They analyze the HARMONi trial results, noting progression-free survival benefits but missed statistical significance in overall survival, complicated by a trial population weighted 60% toward Asian patients. The episode contrasts Akeso's path with BioNTech's purchase of a priority review voucher and highlights Intellia's upcoming March 2027 deadline for its CRISPR therapy lonvo-z.